
Validea's guru fundamental report assigns Lam Research Corporation (LRCX), a large-cap semiconductor stock, an 86% rating using its Warren Buffett-inspired "Patient Investor" model. This strong score highlights LRCX's alignment with criteria for predictable profitability and low debt, passing most fundamental tests including earnings predictability and free cash flow, though it failed on return on total capital. The assessment suggests LRCX could be a compelling consideration for long-term, value-oriented portfolios.
According to a Validea fundamental report, Lam Research Corporation (LRCX) scores a high 86% on the "Patient Investor" model, which is based on Warren Buffett's investment strategy. This score, considered strong by the model's standards, suggests the large-cap semiconductor firm aligns well with criteria emphasizing predictable long-term profitability, low debt, and reasonable valuations. The analysis highlights LRCX's fundamental strengths, as it passed key tests for Earnings Predictability, Debt Service, Free Cash Flow, and Return on Equity. Furthermore, the company's positive marks for Use of Retained Earnings and Share Repurchase indicate efficient capital management and shareholder-friendly policies. The only notable weakness identified by the model was a failure to meet the criterion for Return on Total Capital, suggesting a potential area for further scrutiny despite the otherwise robust profile. The highly positive per-ticker sentiment score of 0.85 for LRCX corroborates the report's bullish assessment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment